



**EVA
PHARMA**



**Innovation to
Sustainable Access**



Patient-centered end-to-end solutions:

**Sustain
access**

Develop

Innovate

650 MAs in
40+ countries,
including **24** EU countries,
UK, Canada, Latin America,
Asia & Africa.

11 Different
dosage forms at
4 manufacturing
sites.

250 scientists at
2 research centers.
5000 strong team.

**1M
Packs
Daily**

Since 1917,

EVA Pharma has been dedicated to improving access to high-quality, affordable medicines around the world, focusing on three core pillars:



Innovation



Development



Sustainable Access

The company leverages cutting-edge technology at **two research centers** bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.

Comprehensive Portfolio:

Ensuring sustainable access to unmet disease areas, the company's product portfolio focuses on twelve therapeutic areas to meet both local and international demand.



Affiliate Companies

Limitless Naturals:

A longevity brand for ambitious individuals across global markets, Limitless Naturals goes beyond traditional supplements to deliver a structured longevity architecture across five pillars: **restorative sleep, daily exercise, smart nutrition, emotional health, and targeted supplementation.**

Backed by over 100 years of pharmaceutical expertise, Limitless ensures clinical-grade bioavailability and real, sustained impact over time delivered through a diverse range of advanced dosage forms, including tablets, ODFs, syrups, powders, and more, tailored for optimal absorption and convenience. This is the limitless lifestyle: practical, proven and built to last.

LIMITLESS
— NATURALS —

EVA Vet Science:

Centered on supporting veterinarians in conquering their daily challenges, our high-quality animal health products, including vaccines, medicines, and feed additives, are meticulously crafted to meet international standards of excellence.

With our unwavering dedication to quality, innovation, and social impact, EVA Vet Science stands ready to fill crucial market gaps and promote the overall health and prosperity of our beloved animal companions.



Research & Development Capabilities

EVA Pharma's R&D is the engine of innovation, responsible for transforming scientific insights into tangible products.

From formulation design to process development, the team ensures every product is optimized for quality, efficacy, and scalability.

It is the largest dedicated pharmaceutical development and services facility in the MENA region, featuring state-of-the-art R&D laboratories and a pilot area equipped with top-tier machinery, all operating in full compliance with GMP and GLP standards.



API synthesis



Drug product formulation




Method Development



Value Added Medicines


Research & Development Capabilities

Our fully equipped research & development hub handles the complete mRNA vaccine development lifecycle - from digital sequencing to final drug formulation.



Global Quality; Global Health

EVA Pharma's state-of-the-art manufacturing facilities are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple global regulatory authorities.



Manufacturing Capabilities

Haram Manufacturing Complex
114 million medicines / year



10th of Ramadan Facility
12,000 sqm – 22 million medicines / year



6th of October Manufacturing Complex
125,000 sqm - 206 million medicines / year



EVA Pharma Research & Manufacturing Complex (Sudair, Saudi Arabia)
50,000 sqm - 990 million medicines / year



Limitless Naturals Facility
3000 sqm - 26 million medicines / year




1997

2014

2015

2023

2024



The Power of Collaboration

We believe collaboration brings innovation to life.

- **End-to-end partnerships:** from API to finished product.
- **Flexible models:** CMO/CDMO, tech-transfer, co-development, licensing.
- **Seamless lifecycle management:** regulatory, logistics and market access.
- **Driving future growth:** pipeline investment and innovation ecosystem.



Over **600** million doses delivered sustainably to global partners

Out-licensing in **46** countries — across EU, UK, Canada, Latin America, Asia & Africa

71 active global CMO/CDMO projects, including Canada, with U.S. market as a key upcoming milestone

Tailored Models for Every Collaboration

Out-Licensing

Enabling Global Health

- European Product Portfolio
- Reliable FDF Supply
- Innovative & Differentiated Dosage Forms
- First-to-Market Generics

CDMO

Innovation to Patient's Hands

- End-to-end: molecule to commercial product
- First-of-its-kind R&D: mRNA & AI-driven
- 5,000+ experts, 250+ researchers
- Agile, optimized, and fast-to-market solutions

CMO

Your Trusted Manufacturing Partner

- Wide range of dosage forms
- Specialized facilities: oncology, biologics & vaccines
- Scalable, high-quality global supply
- Dedicated project management for seamless execution

In-licensing

Accessible Next-Generation Therapies

- Biosimilars
- Vaccines
- mRNA technology
- Hormones

Sustainable Impact:

We have a record of successful collaborations in a variety of areas, being a key provider of life - saving treatments for the most pressing health issues as HIV,HBV, HCV, COVID-19, as well as biologic treatments for diabetes in a list of low - to middle-income countries. And today we are pioneering diverse medical solutions for the Middle East & Africa, through local manufacturing and tech-transfer collaborations.

A record of successful collaborations: Metabolic health biologics:

As part of Lilly's 30x30 initiative, Eli Lilly and EVA Pharma are collaborating to deliver a sustainable supply of human and analogue insulin to people living with type 1 and type 2 diabetes in low- to middle-income countries.

Eli Lilly is supplying API along with technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in Africa.

In December 2024, Lilly and EVA Pharma announced regulatory approval and release of locally manufactured insulin Glargine in Egypt.collaborations.



Localizing Innovative Anti-HIV Medicines:

EVA Pharma signed a non-exclusive, royalty-free voluntary licensing agreement with Gilead, allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries.

EVA Pharma Signs Agreement with Gilead to Boost HIV care in

120 countries



RNA-based Vaccines and Therapeutics:

EVA Pharma, DNA Script, and Quantom Biosciences have signed MoU focusing on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.

The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.



Oncology Medications:

In collaboration with BeOne, EVA Pharma to import, market, promote and distribute BeiGene's flagship Oncology medicines in Egypt.

By leveraging EVA Pharma's deep expertise in distribution, medical affairs, and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt.




Bridging the Middle East & Africa with China:

In 2025, EVA Pharma inaugurated its Hangzhou office through a cooperation agreement with BioPharma Town in Qiantang District to focus on R&D, vaccines, biologics, and advanced therapies.

Moreover, EVA Pharma signed an MoU with Porton Advanced Solutions to expand CAR-T cell therapy development and manufacturing. Additionally, we signed a strategic MoU with CHICO Pharmaceutical to transfer and localize production of advanced oncology APIs, and concluded a strategic supply agreement with Zhejiang Jinhua CONBA Bio-Pharm to enhance cross-border supply chain resilience.



Innovation to Sustainable Access.



info@evapharma.com